| Objective:To detect the efficacy and the side effect of the regimen for Docetaxel Combined with Cisplatin and Dedaplain Chemotherapy in the Treatment with Advanced Non-small Cell Lung Cancer.Methods:A total of 62 patients with advanced non-small cell lung cancer were divided into the Docetaxel Combined with Cisplatin group(group A,n=32)and the Docetaxel Combined with Dedaplain group(group B n=30).In group A, Docetaxel was administrated at the dose of 75mg/m~2 on day 1.Cisplatin was administrated at the dose of 80mg/m~2,divided into 3 days.In group B,Docetaxel was administrated at the dose of 75mg/m~2 on day 1,Dedaplain was administrated at the dose of 80mg/m~2 on day 1.Results:The efficacy of group A was 39.29%and group B was 44%.there was no significant difference between the two groups in curative effect P＞0.05.A higher response rate of digestive reaction and nephrotoxicity(77.4%)occurred in group A,compared to that occurred in group B(60%),with a significant difference between the two groups P＜0.01.There was no significant difference between two groups in the toxicity of kidney.There was a lower incidence of leucopenia response rate (50%)in group A than in group B(76.67%),with a significant difference between the groups P＜0.05.There was a lower thrombocytopenia response rate(6.3%)in group A than in group B(26.67%),with a significant difference between the groups P＜0.05. Conclusions:There is no significant difference between Docetaxel Combined with Cisplatin group and Dedaplain group and there is a lower digestive reaction and nephrotoxicity response rate than in Cisplatin.And the main adverse reaction was myelosuppression,especially thrombocytopenia.Considering that is clinical pragmatic and convenient Nedaplatin is easy to be accepted by the patients and clinicans both.But the anaphylactic shock caused by Nedaplatin should be paid much attention to and done with the clinicans. |
PDF Full Text Request